Skip to content

The effect of of intravenus Lidocaine in comparision with oral Clonidine on heart rate and blood pressure after tracheal intubation in paitients undergo elective surgury with general anesthesia

The effect of of intravenus Lidocaine in comparision with oral Clonidine on hemodynamic responses after direct laryngoscopy and tracheal intubation in paitients undergo elective surgury with general anesthesia

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014102819731N1
Enrollment
86
Registered
2015-01-02
Start date
2012-03-19
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paitients undergo direct laryngoscopy and tracheal intubation with general anesthesia. Other complications of surgical and medical care, not elsewhere classified

Interventions

Intervention 1: In Clonidine group 0.2 mg Clonidine tablet is given 90 minutes before elective surgery and 4 ml normal saline is given intravenously 90 seconds before laryngoscopy and intubation as pl
Treatment - Drugs
In Clonidine group 0.2 mg Clonidine tablet is given 90 minutes before elective surgery and 4 ml normal saline is given intravenously 90 seconds before laryngoscopy and intubation as placebo.
In Lidocaine group a placebo tablest as the same shape of 0.2 mg Clonidine tablet is given 90 minutes before elective surgery and 1 mg/kg Lidocaine is given intravenously 90 seconds before laryngoscop

Sponsors

Tehran University of Medical Science
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria( patients older than 18 years old ; with ASA class I and II).Exclusion criteria ( patients taking drugs that affect hemodynamic or autonomic system ; obese patients(BMI>35) ; patients who have difficult airway(3 miller's criteria +) ; hypovolumic patient ; coronary arteries diseases ; respiratory; renal ; cerebral diseases ; pheochromocytoma ; hypo or hyperthyroidism ; electrocardiographic disturbances ; CHF ,diabetus mellitus ; ,uncontrolled hypertension ; mallampati ; history of allergy or contraindication for drugs used in this study ; pregnant women ; and also patients with more than one laryngoscopic trying for intubation ) .

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Systolic blood presure. Timepoint: 5 minute before induction,just before laryngoscopy and 1-3-5-10 minutes after laryngoscopy and tracheal intubation. Method of measurement: blood presure manometer in mmHg.;Diastolic blood presure. Timepoint: 5 minute before induction,just before laryngoscopy and 1-3-5-10 minutes after laryngoscopy and tracheal intubation. Method of measurement: blood presure manometer in mmHg.;Mean arterial blood presure. Timepoint: 5 minute before induction,just before laryngoscopy and 1-3-5-10 minutes after laryngoscopy and tracheal intubation. Method of measurement: blood presure manometer in mmHg.;Heart rate. Timepoint: 5 minute before induction,just before laryngoscopy and 1-3-5-10 minutes after laryngoscopy and tracheal intubation. Method of measurement: counting heart ratenting.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Alireza Maziar

Tehran University of Medical Science

ar_maziar@razi.tums.ac.irar_maziar@yahoo.com+98 21 8490 1000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026